trending Market Intelligence /marketintelligence/en/news-insights/trending/2C4s3PsY1t26W1iXegMdKg2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Achieve Life Sciences closes merger with OncoGenex Pharmaceuticals

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Achieve Life Sciences closes merger with OncoGenex Pharmaceuticals

Achieve Life Sciences Inc. closed its merger with OncoGenex Pharmaceuticals Inc., making Achieve's stockholders the majority stockholders of OncoGenex.

OncoGenex has been renamed Achieve Life Sciences and the operations and employees of OncoGenex and Achieve have combined to carry on as a fully-integrated late-stage smoking cessation company.

Achieve Life Sciences will continue to be headquartered in Bothell, Wash., with its existing operations in Vancouver, British Columbia.

The new company will be focused on the clinical and commercial development of cytisine, a selective nicotine receptor partial agonist currently in late-stage development for smoking cessation.

Achieve expects to commence a phase 3 trial of cytisine in the U.S. in the first half of 2018.

Immediately before the completion of the merger, on Aug. 1, a 1-for-11 reverse stock split of the company's common stock became effective.

The company's common stock will start trading on the Nasdaq Capital Market on a post-reverse stock split basis under the name Achieve Life Sciences Inc. and the symbol ACHV on Aug. 3.